
In a recent retrospective study, top myeloma specialists collaborated to learn if any specific gene signature indicates whether a patient's myeloma will or won't respond to a standard drug class - the immunomodulators (iMiDs). This is key because iMiDs are a staple myeloma therapy and are many times used for maintenance. There are many patients who would like to know if the drug will have its intended effect as part of their treatment combination.
- TT3a trial (thalidomide in induction and maintenance)
- TT3b trial (thalidomide in induction and lenalidomide in maintenance
- TT6 trial (thalidomide in induction and lenalidomide in maintenance)
- Vincristine, doxorubicin, and dexamethasone (VAD) group of the HOVON65/GMMG-HD4 trial (thalidomide in maintenance).
FINDINGS:
Researchers found that in the first study, 83 patients had IMiD-14 high scores and 92 patients had IMiD-14 low scores. Those with high scores had shorter progression-free survival. (3-year PFS was 52% for the high group and 85% for the low group. The four additional studies supported similar results indicating that the IMiD-14 model has prognostic value in patients with myeloma who are treated with IMiDs. Study authors note that "genes in the model could provide novel targets for IMiD resistance and therapeutic intervention."
about the author
Jennifer Ahlstrom
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of HealthTree Foundation (formerly Myeloma Crowd).
More on New in Myeloma
Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.
Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.
Thanks to our HealthTree Community for Multiple Myeloma Sponsors:







.svg_7bb6fd32-1b73-4ca9-9a2f-8fd6fc59d528.png?alt=media)